Financial Performance Expectations - The company expects a net loss of between 38 million to 56 million yuan for the fiscal year 2024, compared to a profit of 30.35 million yuan in the same period last year, representing a decline of 225.21% to 284.52%[3]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be a loss of 40 million to 58 million yuan, down 205.11% to 252.40% from a profit of 38.06 million yuan in the previous year[3]. Reasons for Decline - The decline in net profit is attributed to a significant drop in the sales price of the company's main products, including enoki mushrooms, due to market conditions in the vegetable and edible mushroom sectors[5]. - Increased depreciation expenses from completed projects and a cumulative expense of approximately 20 million yuan related to the implementation of the 2022/2023 restricted stock incentive plan also contributed to the loss[5]. Financial Data Communication - The company has communicated with the accounting firm regarding the preliminary financial data, and there are no significant discrepancies in the earnings forecast[4]. - The earnings forecast data is based on preliminary estimates by the company's finance department and has not been audited[8]. - The company emphasizes that there are no major uncertainties affecting the accuracy of this earnings forecast[7]. Investor Advisory - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data[8]. - The company will disclose specific financial data in the 2024 annual report, which will take precedence over the preliminary estimates[8]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3].
华绿生物(300970) - 2024 Q4 - 年度业绩预告